{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:38:07Z","timestamp":1790876287588,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K24AG075234"],"award-info":[{"award-number":["K24AG075234"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS099129"],"award-info":[{"award-number":["R01NS099129"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.parkreldis.2023.105822","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T01:03:36Z","timestamp":1693789416000},"page":"105822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease"],"prefix":"10.1016","volume":"115","author":[{"given":"Danielle S.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-764X","authenticated-orcid":false,"given":"Thanh Phuong","family":"Pham Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly L.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-9657","authenticated-orcid":false,"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-7168","authenticated-orcid":false,"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-7192","authenticated-orcid":false,"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.parkreldis.2023.105822_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2023.105822_bib2","article-title":"Effectiveness and tolerability of mirabegron and behavioral therapy in patients with Parkinson's disease and overactive bladder: a prospective, randomized, placebo-controlled pilot study","volume":"35","author":"Ray","year":"2020","journal-title":"Mov Disord [online serial]"},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105822_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","article-title":"Non-Motor Working Group of the Parkinson Study, Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease","volume":"21","author":"Zesiewicz","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105822_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/nau.24552","article-title":"Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: a double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)","volume":"40","author":"Cho","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.parkreldis.2023.105822_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419843458","article-title":"Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: a pilot study","volume":"12","author":"Gubbiotti","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105822_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150621","article-title":"Associations between anticholinergic burden and adverse health outcomes in Parkinson disease","volume":"11","author":"Crispo","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105822_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2023.105822_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105134","article-title":"Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease","volume":"146","author":"Wilkins","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105822_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.parkreldis.2023.105822_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110531","article-title":"Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury","volume":"130","author":"Leonard","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.parkreldis.2023.105822_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","article-title":"Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis","volume":"69","author":"Vouri","year":"2017","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105822_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14740338.2011.579899","article-title":"Drugs with anticholinergic properties: a current perspective on use and safety","volume":"10","author":"Gerretsen","year":"2011","journal-title":"Expet Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105822_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40266-018-00630-z","article-title":"Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective cohort study","volume":"36","author":"Green","year":"2019","journal-title":"Drugs Aging"},{"issue":"10","key":"10.1016\/j.parkreldis.2023.105822_bib15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamainternmed.2016.4814","article-title":"Patterns of prescription drug use before and after fragility fracture","volume":"176","author":"Munson","year":"2016","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105822_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105822_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol. Urodyn."},{"issue":"11","key":"10.1016\/j.parkreldis.2023.105822_bib18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s00415-005-0855-3","article-title":"Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors","volume":"252","author":"Balash","year":"2005","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.parkreldis.2023.105822_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.parkreldis.2023.105822_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2018.09.005","article-title":"Antimuscarinic use and discontinuation in an older adult population","volume":"80","author":"Vouri","year":"2019","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"9","key":"10.1016\/j.parkreldis.2023.105822_bib21","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"J. Manag. Care Pharm."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105822_bib22","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1097\/SPV.0000000000000744","article-title":"National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder","volume":"27","author":"Linder","year":"2021","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105822_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cger.2019.09.011","article-title":"Management of urologic and sexual dysfunction in Parkinson disease","volume":"36","author":"Margolesky","year":"2020","journal-title":"Clin. Geriatr. Med."},{"issue":"6 Suppl","key":"10.1016\/j.parkreldis.2023.105822_bib24","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J. Urol."},{"issue":"12","key":"10.1016\/j.parkreldis.2023.105822_bib25","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.jamda.2021.08.011","article-title":"Centrally acting anticholinergic drugs used for urinary conditions associated with worse outcomes in dementia","volume":"22","author":"Bishara","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105822_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105822_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10639","article-title":"Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs","volume":"54","author":"Perry","year":"2003","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105822_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.parkreldis.2023.105822_bib29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/pds.4226","article-title":"Evaluation of algorithms to identify delirium in administrative claims and drug utilization database","volume":"26","author":"Kim","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105822_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105822_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/ageing\/afaa033","article-title":"Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease","volume":"49","author":"Abraham","year":"2020","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105822_bib32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202300901X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202300901X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:29:12Z","timestamp":1761179352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202300901X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":31,"alternative-id":["S135380202300901X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105822","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105822"}}